RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Gilead Sciences P/E 2024

Gilead Sciences P/E

9.11

Gilead Sciences Dividend yield

4.59 %

Ticker

GILD

ISIN

US3755581036

WKN

885823

As of Apr 29, 2024, Gilead Sciences's P/E ratio was 9.11, a -46.16% change from the 16.92 P/E ratio recorded in the previous year.

The Gilead Sciences P/E history

Gilead Sciences Aktienanalyse

What does Gilead Sciences do?

Gilead Sciences Inc, also known as Gilead, is an American biopharmaceutical company specializing in the development and production of drugs. It was founded in 1987 by Michael Riordan and has since become one of the largest biopharmaceutical companies in the world. Gilead focuses on developing drugs for difficult-to-treat diseases such as HIV, hepatitis, cancer, and inflammatory diseases. Its business model is divided into three segments: HIV, liver diseases, and oncology. The company has made significant advancements in antiviral therapies and aims to improve patients' lives and cure diseases through the development of new medical products and therapies. In the HIV segment, Gilead offers drugs such as Truvada, Atripla, and Biktarvy. In liver diseases, the company has focused on fighting hepatitis C and offers drugs like Harvoni, Sovaldi, and Epclusa. In the field of oncology, Gilead develops drugs for cancer treatment, particularly targeting specific mutations. The company has made notable progress in this area, such as developing the first approved CAR-T-cell therapy for lymphoma treatment, Yescarta. Gilead has also gained attention through its innovative research and development work, including licensing the CRISPR-Cas9 technology for targeted gene editing. Overall, Gilead Sciences Inc has had a remarkable success story and is considered one of the most significant biopharmaceutical companies globally, setting standards and bringing hope for cure to many people with serious illnesses. Gilead Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Gilead Sciences revenue by segment

In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.

P/E Details

Deciphering Gilead Sciences's P/E Ratio

The Price to Earnings (P/E) Ratio of Gilead Sciences is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Gilead Sciences's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Gilead Sciences is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Gilead Sciences’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Gilead Sciences Stock

What is the price-to-earnings ratio of Gilead Sciences?

The price-earnings ratio of Gilead Sciences is currently 9.11.

How has the price-earnings ratio of Gilead Sciences changed compared to last year?

The price-to-earnings ratio of Gilead Sciences has increased by -46.16% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Gilead Sciences high compared to other companies?

Yes, the price-to-earnings ratio of Gilead Sciences is high compared to other companies.

How does an increase in the price-earnings ratio of Gilead Sciences affect the company?

An increase in the price-earnings ratio of Gilead Sciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Gilead Sciences affect the company?

A decrease in the price-earnings ratio of Gilead Sciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Gilead Sciences?

Some factors that influence the price-earnings ratio of Gilead Sciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Gilead Sciences pay?

Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.59 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.

What is the dividend yield of Gilead Sciences?

The current dividend yield of Gilead Sciences is 4.59 %.

When does Gilead Sciences pay dividends?

Gilead Sciences pays a quarterly dividend. This is distributed in the months of July, October, January, April.

How secure is the dividend of Gilead Sciences?

Gilead Sciences paid dividends every year for the past 15 years.

What is the dividend of Gilead Sciences?

For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.96 %.

In which sector is Gilead Sciences located?

Gilead Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gilead Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gilead Sciences from 3/28/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.

When did Gilead Sciences pay the last dividend?

The last dividend was paid out on 3/28/2024.

What was the dividend of Gilead Sciences in the year 2023?

In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.

In which currency does Gilead Sciences pay out the dividend?

The dividends of Gilead Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank

Andere Kennzahlen von Gilead Sciences

Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.